Assessment of mucosal immunity to HIV-1

Expert Review of Vaccines

Volumn 9, Issue 4, 2010, Pages 381-394

  Jespers, Vicky ^a   Harandi, Ali M ^b   Hinkula, Jorma ^c   Medaglini, Donata ^d   Grand, Roger Le ^e   Stahl Hennig, Christiane ^f   Bogers, Willy ^g   Habib, Raphaelle El ^h   Wegmann, Frank ⁱ   Fraser, Carol ^j   Cranage, Martin ^j   Shattock, Robin J ^h   Spetz, Anna Lena ^k  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d UNIVERSITY OF SIENA   (Italy)

^e INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^f GERMAN PRIMATE CENTER   (Germany)

^g BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^h SANOFI PASTEUR   (France)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j University of London Cranmer Terrace   (United Kingdom)

^k KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Assessment; HIV vaccines; Humans; Macaques; Mice; Mucosal immunity; Rabbits

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; GAMMA INTERFERON; HEMOGLOBIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICROBICIDE; PHOSPHATE BUFFERED SALINE; PROSTATE SPECIFIC ANTIGEN; PROTEINASE INHIBITOR; TOLL LIKE RECEPTOR; WART VIRUS VACCINE;

ANTIBODY TITER; ANTIGEN SPECIFICITY; B LYMPHOCYTE; CANCER SCREENING; CELLULAR IMMUNITY; CHROMATOGRAPHY; CONSENSUS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FECES ANALYSIS; FEMALE GENITAL SYSTEM; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNE DEFICIENCY; IMMUNOCHROMATOGRAPHIC RAPID TEST; INTESTINE BIOPSY; INTESTINE LAVAGE; LUNG LAVAGE; LYMPH NODE; MACACA; MICROARRAY ANALYSIS; MUCOSAL IMMUNITY; NOSE MUCUS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECTUM BIOPSY; RECTUM MUCOSA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SAMPLING; SERODIAGNOSIS; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; SIMIAN IMMUNODEFICIENCY VIRUS; SPECIES COMPARISON; SPECIES DIFFERENCE; SPERM; STANDARDIZATION; T LYMPHOCYTE; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; UTERINE ENDOCERVIX; VAGINA FLORA; VAGINA MUCOSA; VAGINA SECRETION; VAGINAL LAVAGE; VIRUS IMMUNITY; VIRUS TRANSMISSION; ANIMAL; EDUCATION; HIV INFECTIONS; IMMUNOLOGY; STANDARDS; VIROLOGY;

AIDS VACCINES; ANIMALS; EDUCATION; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, MUCOSAL;

EID: 77950618623     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.21     Document Type: Review

References (111)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209-2220 (2009).
2. Nardelli-Haefliger D, Wirthner D, Schiller JT et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J. Natl Cancer Inst. 95, 1128-1137 (2003). (Pubitemid 37045391)
3. Kemp TJ, Garcia-Pineres A, Falk RT et al. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 26, 3608-3616 (2008).
4. Schneider JA, Alam SA, Ackers M et al. Mucosal HIV-binding antibody and neutralizing activity in high-risk HIV-uninfected female participants in a trial of HIV-vaccine efficacy. J. Infect. Dis. 196, 1637-1644 (2007). (Pubitemid 351411961)
5. Cummins JE Jr, Doncel GF. Biomarkers of cervicovaginal inflammation for the assessment of microbicide safety. Sex. Transm. Dis. 36, S84-S91 (2009).
6. Keller MJ, Herold BC. Understanding basic mechanisms and optimizing assays to evaluate the efficacy of vaginal microbicides. Sex Transm. Dis. 36, S92-S95 (2009).
7. Pala P, Gomez-Roman VR, Gilmour J, Kaleebu P. An African perspective on mucosal immunity and HIV-1. Mucosal Immunol. 2, 300-314 (2009).
8. Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat. Rev. Immunol. 8, 447-457 (2008).
9. Buchbinder SP, Mehrotra DV, Duerr A et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the STEP study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881-1893 (2008).
10. Benlahrech A, Harris J, Meiser A et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc. Natl Acad. Sci. USA 106, 19940-19945 (2009).
11. Walker BD, Burton DR. Toward an AIDS vaccine. Science 320, 760-764 (2008).
12. Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat. Med. 15, 866-870 (2009).
13. Hirbod T, Broliden K. Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women. J. Intern. Med. 262, 44-58 (2007).
14. Piacentini L, Fenizia C, Naddeo V, Clerici M. Not just sheer luck! Immune correlates of protection against HIV-1 infection. Vaccine 26, 3002-3007 (2008).
15. Horton RE, Ball TB, Wachichi C et al. Cervical HIV-specific IgA in a population of commercial sex workers correlates with repeated exposure but not resistance to HIV. AIDS Res. Hum. Retroviruses 25, 83-92 (2009).
16. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 10, 11-23 (2009).
17. Harandi AM, Svennerholm B, Holmgren J, Eriksson K. Protective vaccination against genital herpes simplex virus type 2 (HSV-2) infection in mice is associated with a rapid induction of local IFN-g-dependent RANTES production following a vaginal viral challenge. Am. J. Reprod. Immunol. 46, 420-424 (2001).
18. Tengvall S, Lundqvist A, Eisenberg RJ, Cohen GH, Harandi AM. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J. Virol. 80, 5283-5291 (2006).
19. Villavedra M, Carol H, Hjulstrom M, Holmgren J, Czerkinsky C. "PERFEXT": a direct method for quantitative assessment of cytokine production in vivo at the local level. Res. Immunol. 148, 257-266 (1997).
20. Devito C, Zuber B, Schroder U et al. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J. Immunol. 173, 7078-7089 (2004).
21. Parr EL, Parr MB. Immunoglobulin G, plasma cells, and lymphocytes in the murine vagina after vaginal or parenteral immunization with attenuated herpes simplex virus type 2. J. Virol. 72, 5137-5145 (1998).
22. Jiang JQ, Patrick A, Moss RB, Rosenthal KL. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides. J. Virol. 79, 393-400 (2005).
23. Garulli B, Kawaoka Y, Castrucci MR. Mucosal and systemic immune responses to a human immunodeficiency virus type 1 epitope induced upon vaginal infection with a recombinant influenza A virus. J. Virol. 78, 1020-1025 (2004).
24. Ciabattini A, Pettini E, Arsenijevic S, Pozzi G, Medaglini D. Intranasal immunization with vaccine vector Streptococcus gordonii elicits primed CD4(+) and CD8(+) T cells in the genital and intestinal tracts. Vaccine 28(5), 1226-1233 (2009).
25. Lindqvist M, Navabi N, Jansson M et al. Local cytokine and inflammatory responses to candidate vaginal adjuvants in mice. Vaccine 28, 270-278 (2009).
26. Blish CA, Sather DN, Sellhorn G et al. Comparative immunogenicity of subtype a human immunodeficiency virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes. J. Virol. 84(5), 2573-2584 (2009).
27. Zolla-Pazner S, Cohen S, Pinter A et al. Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. Virology 392, 82-93 (2009).
28. Dey B, Svehla K, Xu L et al. Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog. 5, e1000445 (2009).
29. Burioni R, Mancini N, De Marco D et al. Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site. PLoS One 3, e3423 (2008).
30. Barberini F, Correr S, De Santis F, Motta PM. The epithelium of the rabbit vagina: a microtopographical study by light, transmission and scanning electron microscopy. Arch. Histol. Cytol. 54, 365-378 (1991).
31. Winchell JM, Van Kruiningen HJ, Silbart LK. Mucosal immune response to an HIV C4/V3 peptide following nasal or intestinal immunization of rabbits. AIDS Res. Hum. Retroviruses 13, 881-889 (1997).
32. Zinckgraf JW, Winchell JM, Silbart LK. Antibody responses to a mucosally delivered HIV-1 gp120-derived C4/V3 peptide. J. Reprod. Immunol. 45, 99-112 (1999).
33. Castle PE, Rodriguez AC, Bowman FP et al. Comparison of ophthalmic sponges for measurements of immune markers from cervical secretions. Clin. Diagn. Lab. Immunol. 11, 399-405 (2004).
34. Koopman G, Bogers WM, van Gils M et al. Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques. J. Med. Virol. 79, 474-482 (2007).
35. Salvato MS, Emau P, Malkovsky M et al. Cellular immune responses in rhesus macaques infected rectally with low dose simian immunodeficiency virus. J. Med. Primatol. 23, 125-130 (1994).
36. Polyanskaya N, Bergmeier LA, Sharpe SA et al. Mucosal exposure to subinfectious doses of SIV primes gut-associated antibody-secreting cells and T cells: lack of enhancement by nonneutralizing antibody. Virology 279, 527-538 (2001).
37. Hudgens MG, Gilbert PB, Mascola JR et al. Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments. J. Infect. Dis. 200, 609-613 (2009).
38. Mederle I, Le Grand R, Vaslin B et al. Mucosal administration of three recombinant Mycobacterium bovis BCG-SIVmac251 strains to cynomolgus macaques induces rectal IgAs and boosts systemic cellular immune responses that are primed by intradermal vaccination. Vaccine 21, 4153-4166 (2003).
39. Macpherson AJ, McCoy KD, Johansen FE, Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunol. 1, 11-22 (2008).
40. Kozlowski PA, Lynch RM, Patterson RR et al. Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody. J. Acquir. Immune Defic. Syndr. 24, 297-309 (2000).
41. Caufour P, Le Grand R, Cheret A et al. Longitudinal analysis of CD8(+) T-cell phenotype and IL-7, IL-15 and IL-16 mRNA expression in different tissues during primary simian immunodeficiency virus infection. Microbes Infect. 3, 181-191 (2001).
42. Anderson DJ, Williams DL, Ballagh SA et al. Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: effects on markers of inflammation and innate immunity in cervicovaginal fluid. Am. J. Reprod. Immunol. 61, 121-129 (2009).
43. Fichorova RN. Guiding the vaginal microbicide trials with biomarkers of inflammation. J. Acquir. Immune Defic. Syndr. 37(Suppl. 3), S184-S193 (2004).
44. Mauck CK, Ballagh SA, Creinin MD et al. Six-day randomized safety trial of intravaginal lime juice. J. Acquir. Immune Defic. Syndr. 49, 243-250 (2008).
45. Schwartz JL, Mauck C, Lai JJ et al. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. Contraception 74, 133-140 (2006).
46. Fichorova RN, Richardson-Harman N, Alfano M et al. Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal. Chem. 80, 4741-4751 (2008).
47. Gravitt PE, Hildesheim A, Herrero R et al. Correlates of IL-10 and IL-12 concentrations in cervical secretions. J. Clin. Immunol. 23, 175-183 (2003).
48. Hildesheim A, McShane LM, Schiffman M et al. Cytokine and immunoglobulin concentrations in cervical secretions: reproducibility of the Weck-Cel collection instrument and correlates of immune measures. J. Immunol. Methods 225, 131-143 (1999).
49. Quesnel A, Cu-Uvin S, Murphy D et al. Comparative analysis of methods for collection and measurement of immunoglobulins in cervical and vaginal secretions of women. J. Immunol. Methods 202, 153-161 (1997).
50. Snowhite IV, Jones WE, Dumestre J et al. Comparative analysis of methods for collection and measurement of cytokines and immunoglobulins in cervical and vaginal secretions of HIV and HPV infected women. J. Immunol. Methods 263, 85-95 (2002).
51. Belec L, Meillet D, Levy M et al. Dilution assessment of cervicovaginal secretions obtained by vaginal washing for immunological assays. Clin. Diagn. Lab. Immunol. 2, 57-61 (1995).
52. Safaeian M, Kemp T, Falk RT et al. Determinants and correlation of systemic and cervical concentrations of total IgA and IgG. Cancer Epidemiol. Biomarkers Prev. 18, 2672-2676 (2009).
53. Alexander R, Mestecky J. Neutralizing antibodies in mucosal secretions: IgG or IgA? Curr. HIV Res. 5, 588-593 (2007).
54. Jones HE, Wiegerinck MA, Nieboer TE, Mol BW, Westhoff CL. Women in the Netherlands prefer self-sampling with a novel lavaging device to clinician collection of specimens for cervical cancer screening. Sex Transm. Dis. 35, 916-917 (2008).
55. Pudney J, Quayle AJ, Anderson DJ. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol. Reprod. 73, 1253-1263 (2005).
56. Nkwanyana NN, Gumbi PP, Roberts L et al. Impact of human immunodeficiency virus 1 infection and inflammation on the composition and yield of cervical mononuclear cells in the female genital tract. Immunology 128, e746-e757 (2009).
57. Passmore JA, Milner M, Denny L et al. Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia. Immunology 119, 507-514 (2006).
58. Prakash M, Patterson S, Kapembwa MS. Evaluation of the cervical cytobrush sampling technique for the preparation of CD45+ mononuclear cells from the human cervix. J. Immunol. Methods 258, 37-46 (2001).
59. Biasin M, Caputo SL, Speciale L et al. Mucosal and systemic immune activation is present in human immunodeficiency virus-exposed seronegative women. J. Infect. Dis. 182, 1365-1374 (2000).
60. Kaul R, Plummer FA, Kimani J et al. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J. Immunol. 164, 1602-1611 (2000).
61. Gumbi PP, Nkwanyana NN, Bere A et al. Impact of mucosal inflammation on cervical human immunodeficiency virus (HIV-1)-specific CD8 T-cell responses in the female genital tract during chronic HIV infection. J. Virol. 82, 8529-8536 (2008).
62. Rebbapragada A, Wachihi C, Pettengell C et al. Negative mucosal synergy between herpes simplex type 2 and HIV in the female genital tract. Aids 21, 589-598 (2007).
63. Levine WC, Pope V, Bhoomkar A et al. Increase in endocervical CD4 lymphocytes among women with nonulcerative sexually transmitted diseases. J. Infect. Dis. 177, 167-174 (1998).
64. Huskens D, Vermeire K, Profy AT, Schols D. The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1. Antiviral Res. 84, 38-47 (2009).
65. Hjelmevoll SO, Olsen ME, Sollid JU et al. Clinical validation of a real-time polymerase chain reaction detection of Neisseria gonorrheae porA pseudogene versus culture techniques. Sex Transm. Dis. 35, 517-520 (2008).
66. Mauck CK, Doncel GF. Biomarkers of semen in the vagina: applications in clinical trials of contraception and prevention of sexually transmitted pathogens including HIV. Contraception 75, 407-419 (2007).
67. Kozlowski PA, Williams SB, Lynch RM et al. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J. Immunol. 169, 566-574 (2002).
68. Crucitti T, Jespers V, Van Damme L, Van Dyck E, Buve A. Vaginal microbicides can interfere with nucleic acid amplification tests used for the diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae infection. Diagn. Microbiol. Infect Dis. 57, 97-99 (2007).
69. Gherardi MM, Perez-Jimenez E, Najera JL, Esteban M. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J. Immunol. 172, 6209-6220 (2004).
70. Barassi C, Soprana E, Pastori C et al. Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy. J. Virol. 79, 6848-6858 (2005).
71. Buonaguro L, Visciano ML, Tornesello ML et al. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J. Virol. 79, 7059-7067 (2005).
72. Brave A, Hallengard D, Schroder U et al. Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses. Vaccine 26, 5075-5078 (2008).
73. Medaglini D, Oggioni MR, Pozzi G. Vaginal immunization with recombinant Gram-positive bacteria. Am. J. Reprod. Immunol. 39, 199-208 (1998).
74. VanCott TC, Kaminski RW, Mascola JR et al. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J. Immunol. 160, 2000-2012 (1998).
75. Ciabattini A, Giomarelli B, Parigi R et al. Intranasal immunization of mice with recombinant Streptococcus gordonii expressing NadA of Neisseria meningitidis induces systemic bactericidal antibodies and local IgA. Vaccine 26, 4244-4250 (2008).
76. Spetz AL, Sorensen AS, Walther-Jallow L et al. Induction of HIV-1-specific immunity after vaccination with apoptotic HIV-1/ murine leukemia virus-infected cells. J. Immunol. 169, 5771-5779 (2002).
77. Brave A, Johansson U, Hallengard D et al. Induction of HIV-1-specific cellular and humoral immune responses following immunization with HIV-DNA adjuvanted with activated apoptotic lymphocytes. Vaccine 28(9), 2080-2087 (2009).
78. Lindqvist M, Persson J, Thorn K, Harandi AM. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J. Immunol. 182, 6435-6443 (2009).
79. Li Z, Zhang M, Zhou C et al. Novel vaccination protocol with two live mucosal vectors elicits strong cell-mediated immunity in the vagina and protects against vaginal virus challenge. J. Immunol. 180, 2504-2513 (2008).
80. Curran RM, Donnelly L, Morrow RJ et al. Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses. Vaccine 27, 6791-6798 (2009).
81. Cranage MP, Fraser CA, Stevens Z et al. Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses. Mucosal Immunol. 3, 57-68 (2009).
82. Wang Y, Abel K, Lantz K et al. The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. J. Virol. 79, 14355-14370 (2005).
83. Miller CJ, Kang DW, Marthas M et al. Genital secretory immune response to chronic simian immunodeficiency virus (SIV) infection: a comparison between intravenously and genitally inoculated rhesus macaques. Clin. Exp. Immunol. 88, 520-526 (1992).
84. Lehner T, Bergmeier LA, Tao L et al. Targeted lymph node immunization with simian immunodeficiency virus p27 antigen to elicit genital, rectal, and urinary immune responses in nonhuman primates. J. Immunol. 153, 1858-1868 (1994).
85. Lu FX, Ma Z, Rourke T, Srinivasan S et al. Immunoglobulin concentrations and antigen-specific antibody levels in cervicovaginal lavages of rhesus macaques are influenced by the stage of the menstrual cycle. Infect. Immun. 67, 6321-6328 (1999).
86. Corbett M, Bogers WM, Heeney JL et al. Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic. Proc. Natl Acad. Sci. USA 105, 2046-2051 (2008).
87. Bogers WM, Bergmeier LA, Ma J et al. A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/ HIV infection. AIDS 18, 25-36 (2004).
88. Hidajat R, Xiao P, Zhou Q et al. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J. Virol. 83, 791-801 (2009).
89. Shacklett BL, Cu-Uvin S, Beadle TJ et al. Quantification of HIV-1-specific T-cell responses at the mucosal cervicovaginal surface. AIDS 14, 1911-1915 (2000).
90. Hobbs MM, Steiner MJ, Rich KD et al. Good performance of rapid prostate-specific antigen test for detection of semen exposure in women: implications for qualitative research. Sex Transm. Dis. 36, 501-506 (2009).
91. Raux M, Finkielsztejn L, Salmon-Ceron D et al. Development and standardization of methods to evaluate the antibody response to an HIV-1 candidate vaccine in secretions and sera of seronegative vaccine recipients. J. Immunol. Methods 222, 111-124 (1999).
92. Ghys PD, Belec L, Diallo MO et al. Cervicovaginal anti-HIV antibodies in HIV-seronegative female sex workers in Abidjan, Cote d'Ivoire. AIDS 14, 2603-2608 (2000).
93. Belec L, Ghys PD, Hocini H et al. Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J. Infect. Dis. 184, 1412-1422 (2001).
94. Mestecky J, Jackson S, Moldoveanu Z et al. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res. Hum. Retroviruses 20, 972-988 (2004).
95. Wassen L, Jertborn M. Influence of exogenous reproductive hormones on specific antibody production in genital secretions after vaginal vaccination with recombinant cholera toxin B subunit in humans. Clin. Vaccine Immunol. 13, 202-207 (2006).
96. Hordnes K, Trovik J, Tynning T, Haneberg B. Self-sampled and air-dried cervicovaginal secretions can be used for analyses of mucosal antibodies. J. Immunol. Methods 220, 151-159 (1998).
97. Hirbod T, Kaul R, Reichard C et al. HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS 22, 727-735 (2008).
98. Rohan LC, Edwards RP, Kelly LA et al. Optimization of the Weck-Cel collection method for quantitation of cytokines in mucosal secretions. Clin. Diagn. Lab. Immunol. 7, 45-48 (2000).
99. Levinson P, Kaul R, Kimani J et al. Levels of innate immune factors in genital fluids: association of a defensins and LL-37 with genital infections and increased HIV acquisition. AIDS 23, 309-317 (2009).
100. Benki S, McClelland RS, Emery S et al. Quantification of genital human immunodeficiency virus type 1 (HIV-1) DNA in specimens from women with low plasma HIV-1 RNA levels typical of HIV-1 nontransmitters. J. Clin. Microbiol. 44, 4357-4362 (2006).
101. Boskey ER, Moench TR, Hees PS, Cone RA. A self-sampling method to obtain large volumes of undiluted cervicovaginal secretions. Sex Transm. Dis. 30, 107-109 (2003).
102. Cohen CR, Plummer FA, Mugo N et al. Increased interleukin-10 in the the endocervical secretions of women with non-ulcerative sexually transmitted diseases: a mechanism for enhanced HIV-1 transmission? AIDS 13, 327-332 (1999).
103. Musey L, Hu Y, Eckert L et al. HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women. J. Exp. Med. 185, 293-303 (1997).
104. Kaul R, Thottingal P, Kimani J et al. Quantitative ex vivo analysis of functional virus-specific CD8 T lymphocytes in the blood and genital tract of HIV-infected women. AIDS 17, 1139-1144 (2003).
105. Hirbod T, Kaldensjo T, Lopalco L et al. Abundant and superficial expression of C-type lectin receptors in ectocervix of women at risk of HIV infection. J. Acquir. Immune Defic. Syndr. 51, 239-247 (2009).
106. McGowan I, Elliott J, Cortina G et al. Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056). J. Acquir. Immune Defic. Syndr. 46, 417-425 (2007).
107. Wright PF, Kozlowski PA, Rybczyk GK et al. Detection of mucosal antibodies in HIV type 1-infected individuals. AIDS Res. Hum. Retroviruses 18, 1291-1300 (2002).
108. Critchfield JW, Lemongello D, Walker DH et al. Multifunctional human immunodeficiency virus (HIV) gag-specific CD8+ T-cell responses in rectal mucosa and peripheral blood mononuclear cells during chronic HIV type 1 infection. J. Virol. 81, 5460-5471 (2007).
109. Shacklett BL, Critchfield JW, Lemongello D. Isolating mucosal lymphocytes from biopsy tissue for cellular immunology assays. Methods Mol. Biol. 485, 347-356 (2009).
110. Olsson J, Poles M, Spetz AL et al. Human immunodeficiency virus type 1 infection is associated with significant mucosal inflammation characterized by increased expression of CCR5, CXCR4, and b-chemokines. J. Infect. Dis. 182, 1625-1635 (2000).
111. Ibarrondo FJ, Anton PA, Fuerst M et al. Parallel human immunodeficiency virus type 1-specific CD8+ T-lymphocyte responses in blood and mucosa during chronic infection. J. Virol. 79, 4289-4297 (2005).